



# NORRIS

## MEDICINES LIMITED



Factory : Plot No. 801/P, 901/3-5, GIDC Estate, ANKLESHWAR 393 002. (Gujarat)  
 Regd. Office : Plot No. 801/P, GIDC Estate, ANKLESHWAR 393 002. (Gujarat)  
 Telephone : (02646) 223462, 227530  
 Fax : (02646) 250126  
 E-mail : contact@norrispharma.com  
 Website : www.norrispharma.com  
 CIN : L24230GJ1990PLC086581

### AUDITED FINANCIAL RESULTS FOR THE QUARTER ENDED & YEAR ENDED 31ST MARCH, 2017

(Rs. In Lacs)

Sr. No.	Particulars	Quarter ended			Year ended	
		31-03-2017	31-12-2016	31-03-2016	31-03-2017	31-03-2016
		(Audited)	(Unaudited)	(Audited)	(Audited)	(Audited)
1	<b>Income from Operations</b>					
	(a) Net Sales/ Income from Operations	434.79	526.58	515.73	2043.38	1885.63
	(b) Other Operating Income	2.19	0.00	0.00	2.30	29.68
	<b>Total Income from Operations (Net)</b>	<b>436.98</b>	<b>526.58</b>	<b>515.73</b>	<b>2045.68</b>	<b>1915.31</b>
2	<b>Expenses</b>					
	(a) Cost of materials consumed	248.62	262.32	234.11	1052.05	959.36
	(b) Purchase of stock in trade	0.00	0.00	0.00	0.00	0.00
	(c) Change in inventories of finished goods work in progress and stock-in-trade	-18.46	-36.74	-29.39	-11.97	-29.39
	(d) Employee benefits expense	129.51	145.04	123.63	530.78	483.53
	(e) Depreciation and amortisation expense	21.10	14.50	-34.59	64.60	59.81
	(f) Other Expense	142.90	124.59	114.13	482.36	388.69
	<b>Total Expenses</b>	<b>523.67</b>	<b>509.71</b>	<b>407.89</b>	<b>2117.82</b>	<b>1862.00</b>
3	<b>Profit / (Loss) from operations before Other Income, Finance Costs and Exceptional Items (1-2)</b>	<b>-86.69</b>	<b>16.87</b>	<b>107.84</b>	<b>-72.14</b>	<b>53.31</b>
4	Other Income	12.38	1.21	-9.28	13.96	0.00
5	<b>Profit / (Loss) from ordinary activities before Finance Costs and Exceptional Items (3 ± 4)</b>	<b>-74.31</b>	<b>18.08</b>	<b>98.56</b>	<b>-58.18</b>	<b>53.31</b>
6	Finance Costs	21.08	14.16	10.63	60.12	67.03
7	<b>Profit / (Loss) from ordinary activities after Finance Costs but before Exceptional Items (5 ± 6)</b>	<b>-95.39</b>	<b>3.92</b>	<b>87.93</b>	<b>-118.30</b>	<b>-13.72</b>
8	Exceptional items	0.00	0.00	0.00	0.00	0.00
9	<b>Profit / (Loss) from Ordinary activities before Tax (7 ± 8)</b>	<b>-95.39</b>	<b>3.92</b>	<b>87.93</b>	<b>-118.30</b>	<b>-13.72</b>
10	Tax Expense	41.57	0.00	17.50	41.57	17.50
11	<b>Net Profit / (Loss) from ordinary activities after tax (9 ± 10)</b>	<b>-53.82</b>	<b>3.92</b>	<b>105.43</b>	<b>-76.73</b>	<b>3.78</b>
12	Extraordinary Items (Net of tax expense)	0.00	0.00	0.00	0.00	0.00
13	<b>Net Profit / (Loss) for the period (11 ± 12)</b>	<b>-53.82</b>	<b>3.92</b>	<b>105.43</b>	<b>-76.73</b>	<b>3.78</b>
14	Share of Profit / (Loss) of Associates	0.00	0.00	0.00	0.00	0.00
15	Minority Interest	0.00	0.00	0.00	0.00	0.00
16	<b>Net Profit / (Loss) after taxes, minority interest share of Profit / (Loss) of associates (13 ± 14 ± 15)</b>	<b>-53.82</b>	<b>3.92</b>	<b>105.43</b>	<b>-76.73</b>	<b>3.78</b>
17	Paid-up Equity Share Capital (face value of the share shall be indicated)	992.58	992.58	992.58	992.58	992.58
18	Reserve excluding revaluation reserves as per balance sheet of previous accounting year	0.00	0.00	0.00	0.00	0.00
19	Basic and Diluted EPS before & after extraordinary items	<b>-0.54</b>	<b>0.04</b>	<b>1.05</b>	<b>-0.77</b>	<b>0.04</b>

**Notes:**

- The above Audited Financial Results have been reviewed by the Audit Committee and approved by the Board of Directors at their respective meeting held on 29.05.2017.
- The Company is having one segment only and therefore Segmental Reporting is not applicable.
- There are no exceptional/ extraordinary items during the quarter & year ended 31.03.2017.
- Previous year/period figures have been regrouped/rearranged wherever necessary to make them comparable with current period figures.

For, Norris Medicines Limited

Date : 29.05.2017  
Place : Chennai



Vimal D. Shah  
Managing Director



# NORRIS

## MEDICINES LIMITED



Factory : Plot No. 801/P, 901/3-5, GIDC Estate,  
ANKLESHWAR 393 002. (Gujarat)  
Regd. Office : Plot No. 801/P, GIDC Estate,  
ANKLESHWAR 393 002. (Gujarat)  
Telephone : (02646) 223462, 227530  
Fax : (02646) 250126  
E-mail : contact@norrispharma.com  
Website : www.norrispharma.com  
CIN : L24230GJ1990PLC086581

STATEMENT OF ASSETS AND LIABILITIES	31.03.2017 (Audited)	31.03.2016 (Audited)
<b>I. EQUITY AND LIABILITIES</b>		
<b>(1) Shareholder's Funds</b>		
(a) Share Capital	992.57	992.57
(b) Reserves & Surplus	(536.42)	(458.35)
(2) Share Application money pending allotment		
<b>(2) Non - Current Liabilities</b>		
(a) Long Term borrowings	757.00	748.93
(b) Long Term provisions		
<b>(3) Current Liabilities</b>		
(a) Short Term borrowings	370.72	2.31
(b) Trade payables	356.99	253.79
(c) Other current liabilities	196.37	187.02
(d) Short Term provisions	67.15	65.53
<b>TOTAL</b>	<b>2204.38</b>	<b>1,791.80</b>
<b>II. ASSETS</b>		
<b>(1) Non -current assets</b>		
(a) Fixed Assets		
(i) Tangible assets	997.14	833.60
(ii) Capital Work in Progress		
(b) Non Current investments	0.88	0.88
(c) Deferred tax assets (net)	181.09	139.52
(d) Long Term Loans and Advances	119.57	137.69
<b>(2) Current Assets</b>		
(a) Current investments		
(b) Inventories	368.90	341.95
(c) Trade Receivables	472.47	277.36
(d) Cash & cash equivalents	4.65	-10.76
(e) Short Term Loans and advances	59.68	71.56
(f) Other Current assets		
<b>TOTAL</b>	<b>2,204.38</b>	<b>1,791.80</b>

Date : 29.05.2017  
Place : Chennai

For, Norris Medicines Limited



Vimal D. Shah  
Managing Director